CLINICAL TRIAL / NCT04634552

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Interventional
  • Recruiting
  • NCT04634552

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).